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Abstract
Background
Fabry disease related patients with classical mutation usually exhibit similar sev-
ere phenotype especially concerning renal manifestation.
Methods
A dry blood spot screening (DBS) and the DNA analysis has been performed in
a 48-year-old man (Patient 1) because of paresthesia.
Results
The DBS revealed absent leukocyte a-Gal A enzyme activity while DNA analysis
identified the I354K mutation. Serum creatinine and e-GFR were in normal
range and also albuminuria and proteinuria were absent. The brain MRI
showed ischemic lesions and a diffuse focus of gliosis in the white matter, while
the echocardiogram showed a left ventricular hypertrophy. The renal biopsy
performed in the case index showed a massive deposition of zebra bodies. By a
familiar investigation, it was recognized that his brother (Patient 2) died 2 years
before from sudden death syndrome at the age of 49. He had suffered sporadic
and undiagnosed pain at the extremities, a prior cataract, bilateral neurosenso-
rial hearing loss and left ventricular hypertrophy on Echocardiogram. His
previous laboratory examinations revealed a normal serum creatinine and
the absence of proteinuria. Pedigree analysis of the brothers revealed a high
disease burden among family members, with an affected cousin (Patient 3)
who progressed early to end-stage renal disease (ESRD) that required renal
transplantation.
Conclusions
Here we describe the clinical history of three adult male members of the same
family with the same genotype who manifested different presentation and pro-
gression of the disease, particularly concerning the renal involvement.
Introduction
Fabry disease (OMIM 301500) is a rare X-linked disorder
resulting from deficient activity of the lysosomal enzyme
a-galactosidase A, due to mutations in the a galactosidase
A (GLA) gene localized in the X chromosomal region
q22.1. The enzymatic defect leads to a progressive accu-
mulation of glycosphingolipids in several fluids, cells, and
in most visceral tissues including kidney, heart, brain,
connective tissue, peripheral nerves, and vascular
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endothelium (Desnick et al. 2001). In the classic form of
the disease, the symptoms start in childhood with pain
and paresthesia, while renal manifestations with albumin-
uria and proteinuria manifest in adolescence. During the
second-to-third decades of life, a hypertrophic cardiomy-
opathy occurs, while the renal involvement progresses to
chronic renal failure leading to early end-stage renal dis-
ease (ESRD) that requires dialysis and transplantation. In
male patients with classic Fabry disease, the leukocyte a-
Gal A activity is generally absent or <1%. In 13% of
patients (Spada et al. 2006), the leukocyte a-Gal A activity
is above 10% and symptoms onset occurs in the fourth-
to- fifth decades of life. In these late-onset phenotypes,
the progression and the severity of the disease are milder
and symptoms are mainly represented by cardiac involve-
ment with arrhythmias and hypertrophic cardiomyopathy,
while other signs and symptoms of the disease are mild
or absent (Hsu et al. 2016). The diagnosis in male
patients is based on the detection of a low or absent
plasma or leukocyte a-Gal A activity that must be then
confirmed by DNA analysis. In females the diagnosis is
exclusively based on gene sequencing, since they can show
a-Gal A activity ranging from normal to very low levels
due to the lyonization phenomenon. Moreover, female
patients experience an extreme variability in phenotype
ranging from asymptomatic to classic phenotype
(Echevarria et al. 2016). In Fabry disease, about 770
mutations in the a galactosidase A (GLA) gene have been
described so far (Schiffmann and Ries 2016). Although,
some of these are associated with a classic phenotype and
others to a late-onset phenotype, genotype/phenotype cor-
relation is still controversial. Across the same family, vari-
ability in the phenotype has been often documented
between female members but also among male patients
with late-onset mutations, and between male patients
with severe or mild renal involvement (Redonnet-Vernhet
et al. 1996; Veronik et al. 2004; Rigoldi et al. 2014; Pan
et al. 2016). By contrast, a different renal phenotype
between adult male patients belonging to the same family,
but without any clinical sign of renal damage, has not
been described yet. Here, we describe the clinical history
of three adult male members of the same family: two of
them with the same genotype and one with a high proba-
bility of having the same genotype. All of them mani-
fested different presentation and progression of the
disease, particularly concerning the renal involvement.
Case Report
Here, we describe the clinical history of three adult male
members belonging to the same family affected by the
missense mutation c.1061T>A p.Ile354Lys or I354K
(Fig. 1). Patient 1 is a 48-year-old-man patient recently
diagnosed with Fabry disease with normal renal function
without proteinuria; his brother (Patient 2) died at the
age of 49 from sudden death syndrome with normal renal
function without proteinuria; their cousin (Patient 3, pro-
band of the family) was affected by ESRD and died at the
age of 59 after kidney transplantation.
Patient 1
MaZ is a 48 year-old-man, healthy until 2 years ago. In
2014, he was admitted to hospital because of paresthesia
and hyposthenia on the right-half of his body. The bio-
chemical evaluation showed a serum creatinine level of
0.8 mg/dL with an e-GFR of 78 mL/min/1.73 m2. The
brain MRI demonstrated ischemic lesions at the left pon-
tine side and in the left radial crown, and a diffuse focus
of gliosis in the white matter. The electrocardiogram
showed a PR interval of 125 msec and in the echocardio-
gram (ECHO) a left ventricular hypertrophy was present
#3: proband
# 1# 2
Figure 1. Pedigree of the family. Fabry
male patient. Heterozygous female.
Unaffected patients. Deceased patients.
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with a posterior wall thickness (PWT) of 12 mm and a
interventricular septum thickness (IVS) of 18 mm. Due
to the persistence of pain, 2 years later, a dry blood spot
screening was performed revealing absent a-Gal A enzyme
activity, and DNA analysis identified the variant p.Ile354-
Lys. Subsequent evaluation demonstrated the absence of
angiokeratomas, the presence of cornea verticillata and a
moderate bilateral hearing loss on audiometry. The bio-
chemical investigation showed serum creatinine of
0.7 mg/dL, e-GFR of 96 mL/min/1.73 m2, proteinuria
80 mg/day, and albuminuria 3 mg/mmol. Due to this
atypical presentation of the disease, and after receiving
informed consent, a renal biopsy was performed. The
major findings from light microscopy involve the podo-
cytes, which appeared markedly enlarged, with bubbly,
clear, foamy cytoplasm. Although the glomeruli were nor-
mocellular, the swollen podocytes had a tendency to nar-
row the urinary space. Similar lipid vacuoles were
detected in tubular cells, vascular myocytes, and endothe-
lial cells. By electron microscopy, diagnostic myelin fig-
ures were identified diffusely in the cytoplasm of
podocytes, with variable but less conspicuous involvement
of mesangial cells, glomerular endothelial cells, tubular
epithelial cells (particularly distal), arterial myocytes and
endothelial cells (Fig. 2). Immunofluorescence staining
was negative for deposits. After the conclusion of disease
staging, the patient started enzyme replacement therapy
(ERT) with agalsidase beta at a standard dose.
Patient 2 (brother)
MiZ was a healthy 44-year-old-man when he underwent
an operation for a posterior right cataract. Two years
later, he began to complain of pain and paresthesia at the
upper extremities and a mild bilateral neurosensorial
hearing loss. The CT scan did not demonstrate any white
matter or vascular lesions in the brain. At the age of 47,
further cardiologic examinations with echocardiogram
demonstrated the presence of hypertrophic cardiomyopa-
thy with a severe interventricular septum thickness of
17 mm, while biochemical exams showed a serum crea-
tinine of 0.7 mg/dL, with an e-GFR of 89 mL/min/
1.73 m2. Both albuminuria and proteinuria were in the
normal range (2.5 mg/mmol and 90 mg/day, respec-
tively). In 2011, at the age of 49, he died of sudden death
syndrome; the autopsy documented a massive intracere-
bral hemorrhage as the cause of death.
Patient 3 (proband)
WM was a 28-year-old male when he was referred to our
department for mild proteinuria in 1981. The kidney
biopsy demonstrated typical Fabry disease nephropathy
under optical and ultrastructural analysis. The leukocyte
a-Gal A enzyme activity was totally absent, while the
DNA analysis identified the variant p.Ile354Lys. The sys-
temic evaluation of the patient demonstrated the presence
of cornea verticillata, a posterior bilateral cataract, some
angiokeratomas in the scrotum, a mild bilateral neuro-
sensorial hearing loss, and a moderate IVS on echocar-
diogram. In 1992 the hemodialysis treatment was started,
and 1 year later he received a successful cadaveric kidney
transplant. Immunosuppression was based on steroids,
cyclosporine and azathioprine; on discharge the serum
creatinine was 2 mg/dL and proteinuria was absent.
Afterward, the graft function remained stable over several
years, while a progressive Fabry cardiomyopathy with
chronic atrial fibrillation occurred. In 2001, he started
enzyme replacement therapy (ERT) with a standard dose
of agalsidase beta that was only reduced during the short-
age period. In 2012, he died of chronic heart failure with
a functional renal transplant.
Figure 2. Massive presence of zebra bodies into podocytes and
mesangial matrix of the glomerulus.
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Discussion
We report here the unusual history of two adult male
patients with Fabry disease who have the same missense
mutation p.Ile354Lys because they belonged to the same
family. In addition, the brother of one of these males had a
medical history that raises a high suspicion of also being
affected by the same mutation. All three males exhibited
different phenotypes of the disease with regard to the renal
manifestations. In particular, the proband of the family
(Patient 3) was diagnosed with Fabry disease about
30 years ago at the age of 28, with proteinuria and renal
failure that progressed to ESRD which required renal trans-
plantation (Mignani et al. 2008). He also developed a severe
cardiomyopathy that led to heart failure and death at the
age of 59. In both affected daughters and nieces of this
patient (Patient 3), the disease manifested early with albu-
minuria and proteinuria leading to an early start of ERT
(Fig. 1). The severity of clinical manifestation in the pro-
band, together with the early onset in female siblings,
prompted us to consider this mutation as classic. After the
diagnosis of the proband, we completed family screening
with his reassurance, discovering a further six members
affected by the disease (Fig. 1). However, only subsequently
we found an affected 1st degree cousin (Patient 1) diag-
nosed with Fabry disease by a neurologist without any clin-
ical signs of renal involvement, but with typical Fabry
nephropathy on biopsy. Completing the family history, we
recognized that his brother (Patient 2), who died 5 years
before from a hemorrhagic stroke, had also probably been
affected by Fabry disease, since he had been suffering from
several symptoms of the disease (pain, posterior cataract,
bilateral hearing loss, hypertrophic cardiomyopathy) but
without any sign of renal damage. What surprised us was
the great difference in the severity of renal manifestations
between these three adult males, with the proband affected
by ESRD and two cousins with normal renal function and
without proteinuria or albuminuria. The origin of pheno-
type variability in Fabry disease is quite controversial.
Phenotype variability has already been described many
times in female patients, and also between monozygotic
twins with the same genotype, due to the Lyonization phe-
nomenon (Redonnet-Vernhet et al. 1996; Echevarria et al.
2016). In affected male children and adolescents who are
related, it is common to observe the onset of pain, pareste-
sias, albuminuria, or proteinuria at different ages (Schiff-
mann and Ries 2016). These observations do not strictly
reflect the presence of different phenotypes, but rather just
the expression at different ages of disease signs and symp-
toms onset. A high interfamilial variability has been previ-
ously documented in a Slovenian family. In this report,
however, together with males on ESRD, some other family
members with normal renal function had already presented
renal clinical signs with overt proteinuria (Veronik et al.
2004). More recently, in four Italian pedigrees, several cases
of interfamilial variability have been documented, but some
males already had albuminuria and their age was not indi-
cated (Rigoldi et al. 2014). Renal variability has been docu-
mented recently in a large cohort of Chinese patients, and
in particular in a family with the R301Q mutation, but this
is now considered to be a late-onset variant (Pan et al.
2016).
Our findings confirm previous data on intrafamilial
variability in hemizygous males with classical Fabry dis-
ease. However, in the family members presented here,
two of the three males with the same mutation (and
absent a-Gal A enzyme activity) had no clinical signs of
renal involvement, despite the renal biopsy in one of
them showed a massive deposition of substrate. To our
knowledge, this is the first case of related males having
no clinical signs of renal involvement at this age. The
reason for the phenotypic variability among male mem-
bers of the same family with the same classic mutation is
still not clear. Several hypotheses have been suggested
such as the presence of concomitant environmental fac-
tors, or the action of modifier genes that could influence
the phenotype of Fabry disease. The consequence of this
variability may be the lack of reliability and prognostic
value of genotype, in particular of classic genotype. Often,
it happens that clinicians start ERT in affected asymp-
tomatic children only because they are the offspring of
adults with classic mutations which are responsible for
severe disease burden. In the majority of cases, this
approach is right, but we should not exclude the possibil-
ity of a different phenotypical outcome. Therefore, this
report should prompt us to be careful in the genetic
counseling of family members, and in particular when
predicting the disease course and consequently deciding if
and when to start ERT in Fabry disease patients.
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